Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nanomix Corporation

http://www.nano.com

Latest From Nanomix Corporation

Sonica Health Develops Wearable For Early Warning Of COVID-19

The US government is helping Sonica develop ADAM, a patch monitor that tracks the user's breathing patterns and other physiologic signals to detect SARS-CoV-2 infections.

Coronavirus COVID-19 Infectious Diseases

COVID-19: Nanomix Wins BARDA Funding For Mobile Point-Of-Care Assay

The US government’s Biomedical Advanced Research and Development Authority has awarded Nanomix up to $570,000 to develop a SARS-CoV-2 test for its portable, rapid Nanomix eLab analyzer.

Coronavirus COVID-19 Infectious Diseases

Shrinking Discovery

The theory that smaller is better--as it is has been in the computer industry--is now driving enthusiasm for nanotechnology, a term that refers to the process of manipulating materials at atomic scale. New players are crowding under this hot rubric, including many working at not nearly so small a scale. Drug discovery methods are among the most compelling near-term nano-applications, but start-ups face challenges like those met by micro-scale pioneers Affymetrix and Caliper. Firms must show they can physically create systems they describe, and that teeny discovery methods actually matter for bench scientists. Business models in this emerging sector reflect the difficulties of harnessing novel science in ways that will satisfy drugmakers who've become extra-tough customers under pressure to deliver commercial results in a shifting, financially depressed market. Some start-ups are working on a fee-for-service basis, on specific projects that address customers' immediate needs. Others are deliberately doing development work on their own, gathering data to attract partnerships that may prove all the more rewarding because of their measured starts.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Research, Analytical Equipment & Supplies
  • In Vitro Diagnostics
    • Biosensors
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Other Names / Subsidiaries
    • Boston Therapeutics, Inc.
    • Nanomix, Inc.
UsernamePublicRestriction

Register